New combo therapy targets tough lymphoma in early trial
NCT ID NCT06249191
First seen Jun 27, 2026 · Last updated Jul 08, 2026 · Updated 2 times
Summary
This study tests whether adding mosunetuzumab, an antibody that helps the immune system attack cancer, to standard chemotherapy can safely treat aggressive B-cell lymphomas. About 30 adults with untreated high-grade or diffuse large B-cell lymphoma will receive the combination. Researchers will monitor side effects and check if tumors shrink or disappear.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- mosunetuzumab (a monoclonal antibody) combined with chemotherapy (etoposide, doxorubicin, vincristine, cyclophosphamide, prednisone)
- What this could lead to
- If successful, this combination could offer a more effective first-line treatment for aggressive B-cell lymphomas, potentially improving remission rates.
- What could go wrong
- This is an early-phase trial with only 30 participants, so results may not apply broadly. The combination may cause serious side effects like cytokine release syndrome or nerve toxicity.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for DIFFUSE LARGE B-CELL LYMPHOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
OHSU Knight Cancer Institute
RECRUITINGPortland, Oregon, 97239, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can immune cells plus a checkpoint drug outsmart lymphoma?
- Can an immune booster outsmart brain lymphoma?
- A shot at safer CAR t: early brain protection for lymphoma patients?
- Can donor immune cells be engineered to fight blood cancer?
- Can a simple blood test spot lymphoma earlier?
- What happens years after CAR-T therapy? a study aims to find out